| HOME >> MEDICINE >> TECHNOLOGY |
(2)
To exclude certain integration costs and separation benefits incurred in connection with continued efforts to enhance the company's operations of $11,110 and amortization of customer relationships of $2,757.
(3)
To exclude milestone payments to partners.
(4)
To exclude asset impairment charges.
(5)
To exclude acquisition-related costs of $3,876 and a gain of $(127) recorded to reflect the change in fair value of the contingent consideration associated with the Qualitest acquisition.
(6)
To exclude additional interest expense as a result of adopting ASC 470-20.
(7)
To exclude the unamortized debt issuance costs written off and recorded as a loss on extinguishment of debt upon our 2012 prepayments on our Term Loan indebtedness.
(8)
To reflect the cash tax savings results from our recent acquisitions and the tax effect of the pre-tax adjustments above at applicable tax rates. Three Months Ended March 31, 2011 (unaudited) Actual Reported (GAAP) AdjustmentsAdjustedREVENUES
$
560,026
$
8212;$
560,026COSTS AND EXPENSES:Cost of revenues
231,558
(50,997)
(1)
180,561Selling, general and administrative
159,386
(3,462)
(2)
155,924Research and development
42,130
(11,001)
(3)
31,129Acquisition-related items, net
6,073
(6,073)
(4)
—OPERATING INCOME
$
20,879
$
71,533$
92,412INTEREST EXPENSE, NET
18,790
(4,541)
(5)
14,249OTHER EXPENSE, NET
348
—348INCOME BEFORE INCOME TAX
$
,741
$
76,074$
77,815
'/>"/>
| SOURCE Endo Copyright©2010 PR Newswire. All rights reserved |